The show takes place in Hannover, Germany from 5-7 October, and the Berlin based company will present its findings to the international audience of experts.
The Biotechnica trade show is an annual event for biotechnology and the life sciences. It covers the entire spectrum of biotechnology, including fundamentals and equipment, and bio-informatics and services, and Organobalance see it as the perfect opportunity to display its research, particularly regarding white biotechnology.
“A close and continuous exchange with our customers and the scientific community is indispensable to us. Biotechnica as the leading biotechnology trade show provides a valuable platform for us”, said Professor Christine Lang, managing director of Organobalance.
For its activities in the field of white biotechnology, Organobalance has put to use its experience with baker’s yeast Saccharomyces cerevisiae as a production organism.
The company says it has developed numerous yeast strains suitable for the sustainable and cost-effective production of a variety of substances and sees great growth potential in this field.
Organobalance specialise in strain development and microbiological screening working in close cooperation with renowned industry partners, to develop new biological products for the cosmetic industry amongst others.
“Our outstanding knowhow and a collection of more than 8000 different bacteria and yeast strains provide a unique basis for our research work. For our own projects, but predominantly for our collaboration partners we use our collection of microorganisms to develop new active substances and production methods for innovative products to be used in the fields of pharmaceutics, nutrition, animal nutrition and personal care”, Professor Lang went on to explain.
Ongoing research since 2001
Since 2001, the Berlin-based company has been doing research - primarily for clients from the fields of red, white and green biotechnology - on probiotic lactobacilli and yeasts, identifying their beneficial potential and rendering them suitable for use.
Recently, Organobalance has focused on the development of pilot processes for the production of protective substances that counteract pathogenic bacteria and cosmetic ingredients that help restore the equilibrium of the skin flora. The company claims it is now in a position to offer clients standardised specimens for application tests.